409 related articles for article (PubMed ID: 26680633)
1. Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases.
Marquez-Medina D; Popat S
Clin Transl Oncol; 2016 Aug; 18(8):760-8. PubMed ID: 26680633
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
Usui K; Sugawara S; Nishitsuji M; Fujita Y; Inoue A; Mouri A; Watanabe H; Sakai H; Kinoshita I; Ohhara Y; Maemondo M; Kagamu H; Hagiwara K; Kobayashi K;
Lung Cancer; 2016 Sep; 99():131-6. PubMed ID: 27565928
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion.
Kitamura K; Kubota K; Ando M; Takahashi S; Nishijima N; Sugano T; Toyokawa M; Miwa K; Kosaihira S; Noro R; Minegishi Y; Seike M; Yoshimura A; Gemma A
Cancer Chemother Pharmacol; 2013 Feb; 71(2):457-61. PubMed ID: 23178954
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of bevacizumab in non-squamous, non-small-cell lung cancer patients with malignant pleural effusion.
Di W; Yue C; Ziran Z; Jie Z; Jun N; Ling D; Weiheng H; Xiaoling C; Xiangjuan M; Guangming T; Jindi H; Sen H; Yang W; Jieran L; Jian F
Future Oncol; 2022 Feb; 18(6):669-677. PubMed ID: 35080187
[No Abstract] [Full Text] [Related]
7. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
[TBL] [Abstract][Full Text] [Related]
8. Novel therapies for malignant pleural effusion: Anti‑angiogenic therapy and immunotherapy (Review).
He D; Ding R; Wen Q; Chen L
Int J Oncol; 2021 Mar; 58(3):359-370. PubMed ID: 33650668
[TBL] [Abstract][Full Text] [Related]
9. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.
Ren S; Terman DS; Bohach G; Silvers A; Hansen C; Colt H; Sahn SA
Chest; 2004 Nov; 126(5):1529-39. PubMed ID: 15539723
[TBL] [Abstract][Full Text] [Related]
10. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity.
Roscilli G; De Vitis C; Ferrara FF; Noto A; Cherubini E; Ricci A; Mariotta S; Giarnieri E; Giovagnoli MR; Torrisi MR; Bergantino F; Costantini S; Fenizia F; Lambiase M; Aurisicchio L; Normanno N; Ciliberto G; Mancini R
J Transl Med; 2016 Feb; 14():61. PubMed ID: 26928703
[TBL] [Abstract][Full Text] [Related]
11. Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy.
Xiang Z; Deng X; He W; Yang Q; Ni L; Dehghan Shasaltaneh M; Maghsoudloo M; Yang G; Wu J; Imani S; Wen Q
Ann Med; 2022 Dec; 54(1):1357-1371. PubMed ID: 35543207
[TBL] [Abstract][Full Text] [Related]
12. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Tamiya M; Tamiya A; Yasue T; Nakao K; Omachi N; Shiroyama T; Tani E; Hamaguchi M; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature.
Mori R; Fujimoto D; Ito M; Tomii K
Oncotarget; 2017 Jul; 8(29):48521-48524. PubMed ID: 28591698
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial of endostar combined with cisplatin/ pemetrexed chemotherapy for elderly patients with advanced malignant pleural effusion of lung adenocarcinoma.
Jie Wang X; Miao K; Luo Y; Li R; Shou T; Wang P; Li X
J BUON; 2018; 23(1):92-97. PubMed ID: 29552766
[TBL] [Abstract][Full Text] [Related]
15. Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers.
Sabang RL; Gandhiraj D; Fanucchi M; Epelbaum O
Expert Rev Respir Med; 2018 Feb; 12(2):87-94. PubMed ID: 29235400
[TBL] [Abstract][Full Text] [Related]
16. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H
Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
18. [Progress of Bevacizumab in Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer].
Liu Y; Tian P
Zhongguo Fei Ai Za Zhi; 2019 Feb; 22(2):118-124. PubMed ID: 30827329
[TBL] [Abstract][Full Text] [Related]
19. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
Brosseau S; Assoun S; Naltet C; Steinmetz C; Gounant V; Zalcman G
Future Oncol; 2017 Dec; 13(28):2537-2546. PubMed ID: 29086616
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study.
Takemoto S; Fukuda M; Yamaguchi H; Ikeda T; Akagi K; Tomono H; Umeyama Y; Dotsu Y; Taniguchi H; Gyotoku H; Senju H; Kitazaki T; Nakatomi K; Nagashima S; Fukuda M; Kinoshita A; Soda H; Mukae H
Thorac Cancer; 2020 Feb; 11(2):389-393. PubMed ID: 31851428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]